05/04/2009 - In a setback for the fledgling field of personalized medicine, Medicare has decided not to pay for genetic tests intended to help doctors determine the best dose of the blood thinner warfarin for a particular patient.
In a proposed decision posted on its Web site Monday, the Centers for Medicare and Medicaid Services said that there was not enough evidence that use of the tests improved patients’ health.
But the agency said it would pay for the tests as part of clinical trials to gather such evidence.
* * *
Kathy Hudson, director of the Genetics and Public Policy Center at Johns Hopkins University, agreed with Medicare’s decision. “We should pay for what works,” she said.
Read the full article Gene Test for Dosage of Warfarin Is Rebuffed on the New York Times' Web site.
Pew is no longer active in this line of work, but for more information, visit the Genetics & Public Policy Center Web site or visit the Genetics and Public Policy Centeron PewHealth.org.